News

CEO, Anders Hultman, Commenting on FDA delay due to Covid-19

Jan 20, 2021

This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA delay in an interview with Redeye.

Further strengthening partnerships in Southeast Asia

In the beginning of May, IDL Diagnostics team visited our distributors in Indonesia and the Philippines as part of our ongoing efforts to strengthen local partnerships and stay closely connected to our markets. During our time in Jakarta, we had an in-depth discussion...

read more